

ABSTRACT

The invention relates to the use of *C. elegans* as a model for identifying genes that are involved in lipid or lipoprotein metabolism and which can serve as drug targets. The 5 invention also provides a system for screening drugs useful in the treatment and prevention of diseases associated with undesirable or abnormal levels of lipids (e.g., cholesterol) or lipoproteins (e.g., LDL), such as cardiovascular disorders and dyslipidemia.